The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma
Open accessAbstract
CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking immunotherapies approved for use against large B-cell lymphomas. Although host inflammatory and tumor microenvironmental markers associate with efficacy and resistance, the tumor-intrinsic alterations underlying these phenomena remain undefined. CD19 mutations associate with resistance but are uncommon, and most patients with relapsed disease retain expression of the wild-type receptor, implicating other genomic mechanisms. We therefore leveraged the comprehensive resolution of whole-genome sequencing to assess 51 tumor samples from 49 patients with CAR-19–treated large B-cell lymphoma. We found that the pretreatment presence of complex structural variants, APOBEC mutational signatures, and genomic damage from reactive oxygen species predict CAR-19 resistance. In addition, the recurrent 3p21.31 chromosomal deletion containing the RHOA tumor suppressor was strongly enriched in patients for whom CAR T-cell therapy failed. Pretreatment reduced expression or monoallelic loss of CD19 did not affect responses, suggesting CAR-19 therapy success and resistance are related to multiple mechanisms. Our study showed that tumor-intrinsic genomic alterations are key among the complex interplay of factors that underlie CAR-19 efficacy and resistance for large B-cell lymphomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, lymphoma-intrinsic genomic alterations are suggested to confer resistance of malignant cells against CD19 CAR-T cells20.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
The repertoire of mutational signatures in human cancer
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2020) · Nature · doi:10.1038/s41586-020-1943-3 · Cited by 3,496
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citation
Cited by
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M., Chojnacka, M., Cirrincione, A., Durante, M., Tilmont, R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02491-5 · Cited by 355
Self-citationStein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02234-6 · Cited by 255
Self-citationWang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A. M., Jacobs, M. T., Mcguirk, J. P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01797 · Cited by 191
Self-citationDeterminants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Sworder, B. J., Kurtz, D. M., Alig, S., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. S., Olsen, M. N., Hamilton, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.005 · Cited by 149
Advancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 135
Metadata
- Authors
- Jain, M. D., Ziccheddu, B., Coughlin, C. A., Faramand, R., Griswold, A. J., Reid, K. M., Menges, M., Zhang, Y., Cen, L., Wang, X., Hussaini, M., Landgren, O., Davila, M. L., Schatz, J. H., Locke, F. L., & Maura, F.
- Affiliations
- University of South Florida (US)
- Sylvester Comprehensive Cancer Center (US)
- 4Medical Scientist Training Program,
- University of Miami (US)
- 7Department of Biostatistics and Bioinformatics and
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2022-08-04
- Volume
- 140
- Issue
- 5
- Pages
- 491-503
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC9353150
- OpenAlex
- W4225103147
- Cited by
- 91
- References
- 60
- Citations by year
- 2026: 18 · 2025: 25 · 2024: 13 · 2023: 29 · 2022: 6
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-10-05)
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Multiple Myeloma Research Foundation
- Leukemia and Lymphoma Society
- Moffitt Cancer Center (P30CA076292, CA076292)
- Sylvester Comprehensive Cancer Center, University of Miami Health Systems (P30 CA 240139)
- Rising Tide Foundation
- National Institutes of Health
- U.S. Food and Drug Administration
- National Cancer Institute (CA076292, F30CA265106, CA201594, K23CA201594, P30CA076292, P30CA240139)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CD19 CAR T-cell therapy, large B-cell lymphoma, treatment resistance, structural variants, APOBEC mutational signature, reactive oxygen species, RhoA, tumor genomic alterations, relapsed lymphoma
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Receptors, Antigen, T-Cell, T-Lymphocytes, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Treatment Failure, Antigens, CD19, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. https://app.cochat.ai/papers/10.1182/blood.2021015008
- The paper
- Jain, M. D., Ziccheddu, B., Coughlin, C. A., Faramand, R., Griswold, A. J., Reid, K. M., Menges, M., Zhang, Y., Cen, L., Wang, X., Hussaini, M., Landgren, O., Davila, M. L., Schatz, J. H., Locke, F. L., & Maura, F. (2022). Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. https://doi.org/10.1182/blood.2021015008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.